<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJMM</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Medicine</journal-title></journal-title-group>
<issn pub-type="ppub">1107-3756</issn>
<issn pub-type="epub">1791-244X</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ijmm.2019.4104</article-id>
<article-id pub-id-type="publisher-id">ijmm-43-04-1900</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Effect of amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing on the treatment of renal failure and hypertension by the PI3K/AKT pathway</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Feng</surname><given-names>Liping</given-names></name><xref rid="af1-ijmm-43-04-1900" ref-type="aff">1</xref><xref rid="fn1-ijmm-43-04-1900" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>Su</surname><given-names>Jiahang</given-names></name><xref rid="af2-ijmm-43-04-1900" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>Chi</surname><given-names>Rongxiang</given-names></name><xref rid="af3-ijmm-43-04-1900" ref-type="aff">3</xref><xref rid="fn1-ijmm-43-04-1900" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>Zhu</surname><given-names>Qiao</given-names></name><xref rid="af4-ijmm-43-04-1900" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lv</surname><given-names>Shuguang</given-names></name><xref rid="af4-ijmm-43-04-1900" ref-type="aff">4</xref><xref ref-type="corresp" rid="c2-ijmm-43-04-1900"/></contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Liang</surname><given-names>Wenjing</given-names></name><xref rid="af5-ijmm-43-04-1900" ref-type="aff">5</xref><xref ref-type="corresp" rid="c1-ijmm-43-04-1900"/></contrib></contrib-group>
<aff id="af1-ijmm-43-04-1900">
<label>1</label>Department of Rehabilitation, Yantai Hospital of Tradition Chinese Medicine, Yantai, Shandong 264000, P.R. China</aff>
<aff id="af2-ijmm-43-04-1900">
<label>2</label>Clinical Pharmacy Room, Yantai Hospital of Tradition Chinese Medicine, Yantai, Shandong 264000, P.R. China</aff>
<aff id="af3-ijmm-43-04-1900">
<label>3</label>Department of Nursing, Yantai Hospital of Tradition Chinese Medicine, Yantai, Shandong 264000, P.R. China</aff>
<aff id="af4-ijmm-43-04-1900">
<label>4</label>Department of Cardiology, Yantai Hospital of Tradition Chinese Medicine, Yantai, Shandong 264000, P.R. China</aff>
<aff id="af5-ijmm-43-04-1900">
<label>5</label>Department of Public Health, Yantai Hospital of Tradition Chinese Medicine, Yantai, Shandong 264000, P.R. China</aff>
<author-notes>
<corresp id="c1-ijmm-43-04-1900">Correspondence to: Dr Wenjing Liang, Department of Public Health, Yantai Hospital of Tradition Chinese Medicine, 39 Xingfu Road, Zhifu, Yantai, Shandong 264000, P.R. China, E-mail: <email>ggws2127338@163.com</email></corresp>
<corresp id="c2-ijmm-43-04-1900">Dr Shuguang Lv, Department of Cardiology, Yantai Hospital of Tradition Chinese Medicine, 39 Xingfu Road, Zhifu, Yantai, Shandong 264000, P.R. China, E-mail: <email>lvdocsci@yeah.net</email></corresp><fn id="fn1-ijmm-43-04-1900" fn-type="equal">
<label>&#x0002A;</label>
<p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="ppub">
<month>04</month>
<year>2019</year></pub-date>
<pub-date pub-type="epub">
<day>20</day>
<month>02</month>
<year>2019</year></pub-date>
<volume>43</volume>
<issue>4</issue>
<fpage>1900</fpage>
<lpage>1910</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>09</month>
<year>2018</year></date>
<date date-type="accepted">
<day>08</day>
<month>02</month>
<year>2019</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2019, Spandidos Publications</copyright-statement>
<copyright-year>2019</copyright-year></permissions>
<abstract>
<p>To study the effect and molecular mechanisms of amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing on the treatment methods of renal failure and hypertension. A total of 60 cases of renal failure hypertension were randomly divided into the Control group and the Treatment group. The control group was treated with amlodipine besylate, while the treatment group was treated with amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing. A rat model of renal failure hypertension was established. Rats were divided into the sham group, model group, NC group (treated with amlodipine besylate) and treatment group (treated with amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing). Rats were given drugs at 10-20 weeks of age to observe their general condition and detect changes of blood pressure, blood biochemical indices and urine index. The pathological changes of renal tissue were examined by hematoxylin and eosin staining, and the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)9 were detected by immunohistochemistry. Reverse transcription-quantitative polymerase chain reaction was used to determine mRNA expression of phosphoinositide 3-kinase (PI3K), protein kinase B (AKT) and endothelin (ET)-1 and western blotting was used to detect the expression of phosphorylated (p)-PI3K/PI3K, p-AKT/AKT and p-nuclear factor (NF)-&#x003BA;B p65/NF-&#x003BA;B p65 protein. Systolic and diastolic blood pressures in Treated group patients were significantly lower compared with in Control group patients. The systolic and diastolic blood pressure of rats were significantly decreased and blood urea nitrogen (BUN), carbapenem-resistant Enterobacteriaceae (CRE), N-acetyl-&#x003B2;-D-glucosaminidase (NAG), urine protein (UP) and blood urea protein (BUP), contents were significantly decreased following amlodipine besylate treatment. The expression of VEGF and matrix metallopeptidase 9 protein were significantly decreased, but the expression of PI3K, AKT mRNA and p-PI3K/PI3K, p-AKT/AKT protein were significantly increased. ET-1 mRNA and p-NF-&#x003BA;B p65/NF-&#x003BA;B protein were significantly increased. The pathological alterations of renal tissue were improved and the pathological changes of glomerulus, tubule and interstitium were alleviated. Amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing can effectively reduce the systolic pressure and diastolic pressure of patients, and improve the symptoms and signs of patients, which may be associated with the regulation of the expression of PI3K/AKT pathway, so as to regulate the expression of BUN, CRE, UP, BUP and NAG.</p></abstract>
<kwd-group>
<kwd>amlodipine besylate</kwd>
<kwd>acupoint application</kwd>
<kwd>renal failure</kwd>
<kwd>hypertension</kwd>
<kwd>phosphoinositide 3-kinase</kwd>
<kwd>protein kinase B pathway</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Renal failure is a pathological state of partial or complete loss of renal function. It can be divided into acute and chronic type disease (<xref ref-type="bibr" rid="b1-ijmm-43-04-1900">1</xref>). Acute renal failure is caused by a variety of diseases, resulting in the loss of excretion by the two kidneys over a short period of time (<xref ref-type="bibr" rid="b2-ijmm-43-04-1900">2</xref>). Chronic renal failure (CRF) is a combination of clinical symptoms formed by the development of chronic kidney disease, which is caused by various etiologies (<xref ref-type="bibr" rid="b3-ijmm-43-04-1900">3</xref>). Renal hypertension is mainly due to the increase of blood pressure caused by renal parenchymal diseases and renal artery diseases. It is also called renal hypertension in symptomatic hypertension (<xref ref-type="bibr" rid="b4-ijmm-43-04-1900">4</xref>).</p>
<p>Amlodipine besylate is a dihydropyridine calcium antagonist (<xref ref-type="bibr" rid="b5-ijmm-43-04-1900">5</xref>). The contraction of myocardium and smooth muscle depends on the extracellular calcium ions entering the cell through specific ion channels (<xref ref-type="bibr" rid="b6-ijmm-43-04-1900">6</xref>). Amlodipine besylate selectively inhibits calcium ion transmembrane movement into smooth muscle cells and cardiac muscle cells, and the effect on smooth muscle is greater compared with the effect on the myocardium (<xref ref-type="bibr" rid="b7-ijmm-43-04-1900">7</xref>). The interaction between calcium ions and its calcium channel depends on the gradual rate of binding and dissociation between the receptor and its calcium channel (<xref ref-type="bibr" rid="b8-ijmm-43-04-1900">8</xref>). Amlodipine besylate is a peripheral artery dilator, acting directly on vascular smooth muscle, reducing peripheral vascular resistance, thereby lowering blood pressure. Certain western antihypertensive drugs have a number of shortcomings and side effects, including a decreased libido, liver damage and metabolic abnormalities. Traditional Chinese medicine treatment has a number of advantages, including fewer side effects, improvement of symptoms, protection of target organs, reduction of complications, low price and good patient compliance. Therefore, the use of Chinese medicine combined with western medicine treatment has great advantages over the use of Western medicine alone (<xref ref-type="bibr" rid="b9-ijmm-43-04-1900">9</xref>,<xref ref-type="bibr" rid="b10-ijmm-43-04-1900">10</xref>).</p>
<p>Acupoint application therapy is guided by the holistic view of traditional Chinese medicine. Acupoint application of traditional Chinese medicine nursing (AA-TCM nursing) is the use of the principle of transdermal absorption on the surface of the human body to relieve the pain. Acupoint sticking is widely used in the clinic. It is a safe and stable treatment. Acupoint sticking therapy is a non-invasive pain acupoint therapy based on the theory of meridians and collaterals of traditional Chinese medicine (<xref ref-type="bibr" rid="b11-ijmm-43-04-1900">11</xref>). For a long time, experts and scholars have conducted literature studies on the literature of past dynasties, and investigated the results. Acupoint therapy is not only used to treat common diseases, but also used to treat pulmonary tuberculosis, liver cirrhosis, coronary heart disease, hypertension, infectious diseases and other difficult diseases (<xref ref-type="bibr" rid="b12-ijmm-43-04-1900">12</xref>).</p>
<p>Serine/threonine kinase AKT (also known as protein kinase B or PKB), as a proto oncogene has become a major concern in the medical community, because it serves an important role in regulating various cell functions, including metabolism, growth, proliferation, survival, transcription and protein synthesis (<xref ref-type="bibr" rid="b13-ijmm-43-04-1900">13</xref>). Factors that can activate the cascade amplification of AKT signals, including receptor tyrosine kinase, integrin, B cells and T cell receptors, cytokine receptors, G protein coupled receptors, and other stimuli that can induce phosphatidylinositol by phosphatidylinositol 3 kinase (PI3K) induced by phosphatidyl inositol (PIP3) (<xref ref-type="bibr" rid="b14-ijmm-43-04-1900">14</xref>). These lipids can be used as a mooring site for the protein membrane of the pleckstrin homology domain, including AKT and its upstream activator, phosphoinositide dependent protein kinase-1 (PDK1). PDK1 located in the cell membrane phosphorylates threonine at the 308 site of AKT, resulting in partial activation of AKT. Serine 473 sites are phosphorylated by mammalian target of rapamycin complex 2, which can stimulate the complete enzyme activity of AKT (<xref ref-type="bibr" rid="b15-ijmm-43-04-1900">15</xref>). PI3K associated kinase family members, including DNA-PK, can also phosphorylate AKT serine at 473 sites. In addition, tumor suppressor gene phosphatase and tensin protein homologue protein also inhibits AKT activity by dephosphorylation of PIP3 (<xref ref-type="bibr" rid="b16-ijmm-43-04-1900">16</xref>). Endothelin 1 (ET-1), also known as preproendo-thelin-1, is a potent vasoconstrictor that in humans is encoded by the EDN1 gene and produced by vascular endothelial cells (<xref ref-type="bibr" rid="b17-ijmm-43-04-1900">17</xref>). The protein encoded by this gene is proteolytically processed to release a secreted peptide termed ET-1 (<xref ref-type="bibr" rid="b18-ijmm-43-04-1900">18</xref>).</p>
<p>In the present study, experiments were designed to investigate the effect and molecular mechanisms of amlodipine besylate combined with AA-TCM nursing on the treatment of renal failure and hypertension via the PI3K/AKT pathway.</p></sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title>Patients and methods</title>
<p>The study was approved by the Yantai Traditional Chinese Medicine Hospital (Yantai, China). Informed consent was obtained from all participants. All included patients fulfilled criteria and completed the study.</p></sec>
<sec>
<title>Characteristic of studied groups</title>
<p>A total of 60 hypertensive patients with renal failure from the Department of Cardiology outpatient and hospitalization in the Yantai traditional Chinese Medicine Hospital were included in the study. There were 26 males and 34 females with an average age of 61 years. They were randomly divided into two groups, 30 cases in each group, group Control: Average age (60.80&#x000B1;13.45 years), average duration of treatment (6.43&#x000B1;7.11 years) and male and female ratio (15/15); Treatment group: Average age (61.83&#x000B1;13.03 years), average duration (9.06&#x000B1;9.06 years), and male and female ratio (11/19). The diagnostic scale was formulated according to the guideline 2010 for hypertension prevention and treatment in China (<xref ref-type="bibr" rid="b19-ijmm-43-04-1900">19</xref>). Diagnostic criteria for adult hypertension: i) Systolic pressure is &#x0003E;140 mmHg and (or) diastolic pressure &#x0003E;90 mmHg; ii) serum creatinine &#x0003C;364 <italic>&#x000B5;</italic>mol/l; and iii) different levels of digestive tract symptoms and mild anemia. There was no significant difference in the duration, age, sex and grade of hypertension between the two groups. Causes of renal failure and subsequent treatment are listed as follows: i) Renal failure and hypertension patients over 18 years old; ii) it is in line with grade 1 and 2 hypertension, but no serious cardio pulmonary disease; iii) those taking blood pressure drugs who did not control blood pressure maintained the same dose and dosage during treatment, while those who did not take antihypertensive drugs did not take antihypertensive drugs during treatment; and iv) the patient&#x02019;s informed consent was good, and the compliance was good, respectively. Subjects were excluded from the study if they met these criteria: i) Patients with secondary hypertension; ii) pregnant and lactation women; and iii) poor consent and poor compliance.</p></sec>
<sec>
<title>Blood pressure measurement</title>
<p>The diagnosis of hypertension is based on the diagnostic criteria of hypertension in the guiding principles of new drugs: i) Obvious effect rate: The systolic pressure (systolic blood pressure, SBP) control at 120-140 mmHg level, diastolic pressure (diastolic blood pressure, DBP) control at 70-85 mmHg levels; ii) effective rate: SBP decline is &#x0003E;10 mmHg and DBP control at 60-85 mmHg level; and iii) null and void: None of these standards were reached. Total effective rate of blood pressure control = obvious effect rate + effective rate.</p></sec>
<sec>
<title>Therapeutic method</title>
<p>The Control group was orally administered 75 mg/day amlodipine besylate (H20066824; Beijing Wansheng Pharmaceutical Co., Ltd.). Treatment group orally administered 5 mg/day amlodipine besylate combined with 75 mg/day acupoint application of traditional Chinese medicine nursing (acupoint Neiguan, Yongquan and Sanyinjiao). The prescription of AA-TCM nursing is composed of 2 g psoralen, 0.6 g Wu Zhuyu, 0.6 g cinnamon, 2 g cooked aconite, 0.6 g clove, 1 g ephedra, 2 g mulberry and 2 g Herba Epimedium. When applied to patients, it is advisable to adjust the amount of ginger juice into thick paste and make it into a cone shaped medicinal cake with a diameter of 2 cm. Operation method: The patients&#x02019; acupoints (Neiguan, Yongquan and Sanyinjiao acupoints) were fully exposed by the nurse and routinely disinfected with 75% alcohol. After that, the medicine cakes were placed in the center of the non-woven cloth application (6&#x000D7;7 cm) and fixed on the acupoints for 4-6 h, once a day for 2 weeks.</p></sec>
<sec>
<title>Animals and treatment</title>
<p>A total of 40 Male SHR rats (200&#x000B1;20 g, 6 weeks of age) were purchased from Ji&#x02019;nan PengYue Experimental Animal Breeding Co., Ltd. &#x0005B;Zhangqiu, Jinan, China; quality certificate number, SCXK (Lu) 20140007&#x0005D;. All animals were housed in a controlled environment at 22&#x000B1;1&#x000B0;C and relative humidity (60&#x000B1;10)% under a 12-h dark/light cycle with free access to food and water. Animal experiments were performed by following the National institute of Health (NIH) guidelines (<xref ref-type="bibr" rid="b20-ijmm-43-04-1900">20</xref>). All experimental procedures were approved by the Animal Care and Use Committee of Yantai Hospital of Tradition Chinese Medicine and performed in strict accordance with the People&#x02019;s Republic of China Legislation Regarding the Use and Care of Laboratory Animals.</p>
<p>After two weeks of acclimatisation, the animals were randomly divided into 4 groups, including the Sham operation control group which underwent opening of the abdominal cavity to expose the kidney, but no nephrectomy (Sham group), the Model group, Amlodipine besylate treatment (1 mg/kg/day) group (NC group) and amlodipine besylate (1 mg/kg/day) combined with acupoint sticking therapy group (Treatment group). The acupoints of the rat acupoint application method were selected to be the same as those of the patient. The prepared application was placed on the above acupoints. If the rats bit the application this was fixed with medical tape. One acupoint was treated with one Chinese medicine patch. Each treatment lasted for 1 h and was performed every other day for 6 weeks. The experimental diets were given <italic>ad libitum</italic> for 8 weeks in the form of pellets and the animals were sacrificed following an overnight fast. Then, blood (0.5 ml) was harvested and stored at 4&#x000B0;C. The kidney tissue was collected and stored at &#x02212;80&#x000B0;C for further analysis. All rats were anesthetized with 1% pentobarbital sodium (30 mg/kg). Following strict disinfection, 2/3 of the right kidney was resected. The treated rats were then given access to normal diet and water. At age 9 weeks, the above rats were anesthetized, disinfected again and the whole left kidney was removed to establish an SHR-CRF animal model with only 1/3 of a kidney. After operation, the normal diet and drinking water were restored for 1 week. The rats were fed alone in individual cages. At the age of 10 weeks, rats were fed intragastrically to observe the general condition of rats. The rats were then put into a clean metabolic cage. Following access to normal drinking water, 24 h urine was collected and the volume was measured. T blood pressure of rats was measured by a non-invasive blood pressure meter. SPB and DBP were measured every 2 weeks. Rats were raised to 20 weeks age, after which they received intraperitoneal injection of 3% pentobarbital sodium (40 mg/kg). The rats were anesthetized and blood biochemical test was performed after the carotid artery was excised. Part of the renal tissue was taken to fix for 24 h at room temperature in 10% formalin. The tissues were paraffin was embedded prior to hematoxylin and eosin (H&#x00026;E) staining and immunohistochemistry, and then transferred to &#x02212;80&#x000B0;C refrigerator following freezing with liquid nitrogen, and used for reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blotting detection.</p></sec>
<sec>
<title>Biochemical analysis</title>
<p>Blood samples were placed at room temperature until serum appeared in the upper layer. Serum was separated via centrifugation at 1,000 &#x000D7; g and 4&#x000B0;C for 10 min, and the supernatant was collected and maintained at &#x02212;20&#x000B0;C for preservation. The levels of serum urea nitrogen (BUN), creatinine (CRE), total protein (TP) and albumin (ALB) were determined by an automatic biochemical analyzer. Urine protein (UP) was determined using a UP ELISA Kit (cat. no. DRE9802Ra; Shanghai Lianshuo Biological Technology Co., Ltd., Shanghai, China). The contents of urea nitrogen, urine creatinine, N-acetyl-Glucosaminidase (NAG) in urine, and creatinine clearance (Ccr) were measured by an automatic biochemical analyzer. Endogenous creatinine clearance (ml/kgB.W./min) = concentration of urinary creatinine &#x000D7;24 h urine volume/serum creatinine concentration (ml)/24/60/1,000 &#x000D7; body weight (g).</p></sec>
<sec>
<title>H&#x00026;E staining</title>
<p>After being sacrificed, the renal tissues of the rats were embedded in paraffin and fixed in 10% formalin for at least 24 h at room temperature. The samples were then cut into 5-<italic>&#x000B5;</italic>m pieces and fixed on slides according to the routine procedure. Renal sections were stained with hematoxylin (Beijing Solarbio Science &#x00026; Technology Co., Ltd.) for 5 min at room temperature and washed with tap water. They were differentiated by hydrochloric acid ethanol for 30 sec and soaked for 15 min with water, then placed in eosin dye solution (Beijing Solarbio Science &#x00026; Technology Co., Ltd.), dehydrated for 2 min. Histopathological changes were observed under an Olympus microscope (BX51 Olympus, magnification, 200; Olympus Corporation, Tokyo, Japan).</p></sec>
<sec>
<title>Immunohistochemistry assay</title>
<p>Immunohistochemistry staining of tissue slices for VEGF and matrix metallopeptidase 9 (MMP9) were performed using a VEGF primary antibody (1:1,600; cat. no. 9698; Cell Signaling Technology, Inc., Danvers, MA, USA) and an MMP9 primary antibody (1:325; cat. no. 13667; Cell Signaling Technology, Inc.) in a humidified chamber at 4&#x000B0;C overnight. After rewarming, the tissue slices were incubated with goat horseradish peroxidase-conjugated secondary antibodies against rabbit immunoglobulin (Ig)G (1:1,000; cat. no. 7074; Cell Signalling Technology, Inc.), then dyed with DAB and dehydrated. It was observed under &#x000D7;400 optical microscope (Olympus Corporation). The positive staining was evaluated by a hierarchical system. The score was defined as: 0, no staining; 1, mild staining; 2, moderate staining; 3, strong staining. In order to maintain the consistency of the scores, each part was scored by two inexperienced tissue scientists, and the average value was calculated.</p></sec>
<sec>
<title>Detection of expression level of associated mRNA by RT-qPCR</title>
<p>The total RNA was extracted using the TRIzol kit &#x0005B;Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA; the purity of RNA was qualified by optical density (OD)260/OD280 between 1.8-2.0&#x0005D;. RT was performed with the SuperScript&#x02122; III First-Strand short SuperMix for qPCR retrovirus kit (cat. no. 11752250; Thermo Fisher Scientific, Inc.) according to the manufacturer&#x02019;s protocol. The temperature protocol was as follows: 50&#x000B0;C for 30 min, 85&#x000B0;C for 5 min and termination at 4&#x000B0;C. Master EP realplex2 (Eppendorf, Hamburg, Germany) was used to conduct quantitative PCR (conditions: 94&#x000B0;C for 3 min, 94&#x000B0;C for 30 sec, 55&#x000B0;C for 30 sec, 30 cycles). The relative expression of mRNA were calculated by 2<sup>&#x02212;&#x00394;&#x00394;Cq</sup> method (<xref ref-type="bibr" rid="b21-ijmm-43-04-1900">21</xref>), and the &#x003B2;-actin mRNA was used as a reference to calculate the relative expression levels. Primers (Sangon Biotech Co., Ltd., Shanghai, China) were listed in <xref rid="tI-ijmm-43-04-1900" ref-type="table">Table I</xref>.</p></sec>
<sec>
<title>Western blotting</title>
<p>Total proteins were extracted from tissues according to the whole protein extraction kit (cat. no. BC3710; Beijing Solarbio Science &#x00026; Technology Co., Ltd.). The renal tissues were were mechanically crushed and centrifuged at 3,000 &#x000D7; g and 4&#x000B0;C for 10 min. The supernatant was taken and the protein concentrations of the renal tissues were measured by the bicinchoninic acid kit (Beijing Solarbio Science &#x00026; Technology Co., Ltd.). A total of 30 <italic>&#x000B5;</italic>g samples protein and 10% SDS-PAGE were mixed 1:1. The protein denaturation by heating 5 min at 95&#x000B0;C The protein samples were transferred to polyvinylidene difluoride membrane (Merck KGaA, Darmstadt, Germany) under the semi drying condition of 20V for 30 min (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membranes were washed and blocked with 5% evaporated milk for 2 h at room temperature. Primary antibodies were added, including rabbit anti PI3K (1:1,000; cat. no. 4249), p-PI3K (1:1,000; cat. no. 4228), p-AKT (1:2,000; cat. no. 4060), AKT (1:1,000; cat. no. 4691), p-NF-&#x003BA;B p65 (1:1,000; cat. no. 8214), NF-&#x003BA;B p65 (1:1,000; cat. no. 8242) and rabbit anti &#x003B2;-actin antibody (1:1,000; cat. no. 4970; all from Cell Signaling Technology, Inc.) and incubated at 4&#x000B0;C overnight. After washing 3 times, goat anti-rabbit IgG-horseradish peroxidase (1:1,000; ABIN101988; antibodies-online GmbH, Aachen, Germany) was added and incubated for 1 h. The results were observed and recorded by Roche Elecsys-2010 chemiluminescence (Roche Diagnostics, Basel, Switzerland). Protein expression level were normalized according to the &#x003B2;-actin and quantified by Image J 1.48u (National Institutes of Health, Bethesda, MD, USA) software.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>Data were analysed by SPSS 19.0 statistical software (IBM Corps, Armonk, NY, USA). Each experiment was repeated three times. The results of DBP, SBP, each situation and symptom score following the treatment of hypertensive patients and rats were expressed as the mean &#x000B1; standard deviation. A t-test was used for data analysis between the two groups. One-way analysis of variance was used for data analysis among multiple groups. The least significant difference test was used for subsequent analysis. P&#x0003C;0.05 was considered to indicate a statistically significant difference.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Changes of blood pressure in hypertensive patients with renal failure</title>
<p>There was no significant difference in DBP and SBP between the two groups prior to treatment (P&#x0003E;0.05). Following treatment, the difference between the two groups was statistically significant (P&#x0003C;0.05). The results proved that the treatment group was better than the control group in reducing DBP and SBP (<xref rid="tII-ijmm-43-04-1900" ref-type="table">Table II</xref>). The results demonstrated that amlodipine besylate combined with AA-TCM nursing has obvious therapeutic effect on renal failure and hypertension.</p></sec>
<sec>
<title>Clinical efficacy of treatment of renal failure patients with hypertension</title>
<p>As presented in <xref rid="tIII-ijmm-43-04-1900" ref-type="table">Table III</xref>, there were 30 patients with renal failure in the Control group. The average age of the 25-45 year old patients was 38.60&#x000B1;6.58, including 4 males (80.0%) and 1 female (20.0%). The average age of the 46-65 year old patients was 58.43&#x000B1;6.09, including 8 males (57.1%) and 6 females (42.9%). The average age of the 66-85 year old patients was 73.91&#x000B1;5.80, including 3 males (27.3%) and 8 females (72.7%). Additionally there were 30 patients with renal failure in the treatment group. The average age of 25-45 year old patients was 35.75&#x000B1;9.57, including 3 males (75.0%) and 1 female (25.0%). The average age of 46-65 year old patients was 59.8&#x000B1;3.97, including 4 males (26.7%) and 11 females (73.3%). The average age of 66-85 year old patients was 74.09&#x000B1;4.06, including 4 males (36.4%) and 7 females (63.6%). The results demonstrated that the treatment effect was independent of age and sex (P&#x0003E;0.05).</p></sec>
<sec>
<title>Total effective rate of hypertension in renal failure</title>
<p>After treatment, the two groups&#x02019; blood pressures were significantly reduced. The total effective rate in the Control group was 56.7%, and the total effective rate in the Treatment group was 80%. The difference between the two groups was statistically significant (P&#x0003C;0.05; <xref rid="tIV-ijmm-43-04-1900" ref-type="table">Table IV</xref>).</p></sec>
<sec>
<title>The general condition of the rats</title>
<p>The rats in the Sham group had glossy hair, quick reactions, a normal intake of water and body weight. In the Model group, the rats were depressed, dull fur and sluggish, slow in activity, slow in appetite and slow in growth. Compared with the Model group, the time of occurrence of symptoms in the NC group and Treatment group was delayed to varying degrees, and symptoms improved significantly. Compared with the NC group, the symptoms of the Treatment group improved slightly.</p></sec>
<sec>
<title>Effect of amlodipine besylate combined with AA-TCM nursing on blood pressure in hypertensive rats with renal failure</title>
<p>As presented in <xref rid="f1-ijmm-43-04-1900" ref-type="fig">Fig. 1</xref>, the systolic and diastolic pressure of rats in Model group was significantly increased compared with the Sham group (P&#x0003C;0.05). Compared with the Model group, the systolic and diastolic pressure of the NC group and Treatment group decreased significantly at the beginning of the treatment (12 weeks age), and there was a significant difference (P&#x0003C;0.05). Compared with the NC group, the blood pressure of the Treatment group decreased slightly. The results demonstrated that amlodipine besylate combined AA-TCM nursing exhibited significant antihypertensive effects on renal failure hypertension.</p></sec>
<sec>
<title>Effect of amlodipine besylate combined with AA-TCM nursing on blood biochemical indexes in hypertension rats with renal failure</title>
<p>As presented in <xref rid="f2-ijmm-43-04-1900" ref-type="fig">Fig. 2</xref>, compared with the Sham group, the concentration of TP and ALB in the Model group was not significantly different, but the concentration of BUN and CRE increased significantly (P&#x0003C;0.05). Compared with the Model group, there was no significant difference in the concentrations of TP and ALB between the NC group and the Treatment group following treatment, but the concentrations of BUN and CRE decreased significantly (P&#x0003C;0.05). Compared with the NC group, the concentrations of BUN and CRE in the Treatment group decreased slightly. The results demonstrated that amlodipine besylate combined with AA-TCM nursing had no effect on TP and ALB, and could increase and decrease the concentration of BUN and CRE in the serum of rats.</p></sec>
<sec>
<title>Effect of amlodipine besylate combined with AA-TCM nursing on urine index in hypertension rats with renal failure</title>
<p>As presented in <xref rid="f3-ijmm-43-04-1900" ref-type="fig">Fig. 3</xref>, compared with the Sham group, the content of UP, BUP, CRE and NAG in the Model group increased significantly, and Ccr decreased significantly (P&#x0003C;0.05). Compared with the Model group, the contents of UP, BUP, CRE and NAG in NC group and the Treatment group were significantly decreased, while Ccr was significantly increased (P&#x0003C;0.05). Compared with the NC group, the urine index of group Treatment was closer to the normal value. The results demonstrated that amlodipine besylate combined with AA-TCM nursing could enhance the clearance rate of serum creatinine in rats.</p></sec>
<sec>
<title>Pathological changes of renal tissue in rats</title>
<p>As presented in <xref rid="f4-ijmm-43-04-1900" ref-type="fig">Fig. 4</xref>, the glomerular, renal tubules and interstitial tissue in the Sham group exhibited a normal arrangement and distribution. In the Model group, the following observations were made: The wall of glomeruli was thickened, capillary dilation or occlusion, partial glomerular segmental or spherical sclerosis, mesangial cell proliferation, renal tubules as flat epithelial cells, vacuolating part of epithelial cells, part of renal tubules dilated, interstitial cells and fibroblasts, and interstitial collagen in interstitial cells. While, glomeruli, tubulointerstitial and interstitial lesions in the NC group and Treatment group were relieved. Compared with the NC group, the pathological changes of Treatment group were improved.</p></sec>
<sec>
<title>Effect of amlodipine besylate combined with AA-TCM nursing on VEGF and MMP9 in renal tissue of hypertensive rats with renal failure</title>
<p>As presented in <xref rid="f5-ijmm-43-04-1900" ref-type="fig">Fig. 5</xref>, VEGF was expressed in the renal interstitium and glomerulus, and MMP9 was expressed in the cytoplasm of renal tubular epithelial cells. Compared with the Model group, the scores of VEGF and MMP9 in the NC group and Treatment group decreased significantly (P&#x0003C;0.05). Compared with the NC group, the contents of VEGF and MMP9 in the Treatment group were significantly decreased (P&#x0003C;0.05).</p></sec>
<sec>
<title>Effects of amlodipine besylate combined with AA-TCM nursing on the PI3K/AKT pathway associated mRNA in hypertensive rats with renal failure</title>
<p>As presented in <xref rid="f6-ijmm-43-04-1900" ref-type="fig">Fig. 6</xref>, compared with the Sham group, the mRNA expression of PI3K and AKT in the Model group was significantly decreased, and the mRNA expression of ET-1 increased significantly (P&#x0003C;0.05). Compared with the Model group, the mRNA expression of PI3K and AKT in the NC group and Treatment group increased significantly in hypertensive rats with renal failure, and the mRNA expression of ET-1 was significantly decreased (P&#x0003C;0.05). Compared with the NC group, the mRNA expression of PI3K in the Treatment group was significantly increased (P&#x0003C;0.05), but the mRNA expression of AKT and ET-1 were not significantly changed (P&#x0003E;0.05).</p></sec>
<sec>
<title>Effects of amlodipine besylate combined with AA-TCM nursing on PI3K/AKT pathway associated proteins in hypertensive rats with renal failure</title>
<p>As presented in <xref rid="f7-ijmm-43-04-1900" ref-type="fig">Fig. 7</xref>, compared with the Sham group, the expression of p-PI3K and p-AKT/AKT proteins in hypertensive rats with renal failure in the Model group was significantly decreased, and the expression of p-NF-&#x003BA;B p65/NF-&#x003BA;B p65 protein increased significantly (P&#x0003C;0.05), and the expression of PI3K and p-AKT/AKT proteins in the NC group and Treatment group of hypertensive rats with renal failure was significantly increased and p-NF-&#x003BA;B p65/NF-&#x003BA;B p65 protein decreased significantly compared with those in the Model group (P&#x0003C;0.05). Compared with the NC group, the expression of p-PI3K/PI3K protein in the Treatment group were significantly increased, and the expression of p-AKT/AKT and p-NF-&#x003BA;B p65/NF-&#x003BA;B p65 protein were significantly decreased (P&#x0003C;0.05).</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Renal hypertension is a secondary hypertensive condition, mainly due to renal hypertension and renal artery disease (<xref ref-type="bibr" rid="b22-ijmm-43-04-1900">22</xref>). This disease is mainly characterized by degeneration of glomeruli, interstitial tissue and connective tissue hyperplasia, renal tubule atrophy, small renal artery stenosis or non-specific Takayasu arteritis resulting in substantial damage to the kidney and lack of blood supply (<xref ref-type="bibr" rid="b23-ijmm-43-04-1900">23</xref>). Mucous myofibrillar hyperplasia in the middle layer of renal artery wall forms most small aneurysms, thus the inner wall of renal arterioles protrude like beads, resulting in segmental stenosis of renal artery (<xref ref-type="bibr" rid="b24-ijmm-43-04-1900">24</xref>-<xref ref-type="bibr" rid="b26-ijmm-43-04-1900">26</xref>). Hypertension can cause kidney damage, and the two will promote each other, which will further develop the disease. Therefore, renal hypertension should actively be treated (<xref ref-type="bibr" rid="b27-ijmm-43-04-1900">27</xref>).</p>
<p>The negative inotropic effects of amlodipine besylate were observed <italic>in vitro</italic>, but not in animal experiments (<xref ref-type="bibr" rid="b28-ijmm-43-04-1900">28</xref>). This product does not affect the concentration of plasma calcium. Clinical trials have confirmed its antihypertensive effect. Prolonged use did not cause changes in heart rate or plasma catecholamine (<xref ref-type="bibr" rid="b29-ijmm-43-04-1900">29</xref>). The effect of depressurization is gradual and the difference between peak and valley value is not large. The effect of hypotension is associated with the dose (<xref ref-type="bibr" rid="b30-ijmm-43-04-1900">30</xref>). The change in amplitude is associated with blood pressure prior to treatment. The moderate hypertension patients exhibited improvement compared with mild hypertension patients following administration, whereas the patients with normal blood pressure have no obvious effects (<xref ref-type="bibr" rid="b31-ijmm-43-04-1900">31</xref>). Amlodipine benzoate can directly affect diastolic vascular smooth muscle and have an antihypertensive effect. This product relieves angina by dilating peripheral arteries, reducing peripheral resistance, reducing myocardial oxygen consumption and expanding the coronary arteries of normal and ischemic areas to improve the myocardial supply of patients with coronary spasm (<xref ref-type="bibr" rid="b32-ijmm-43-04-1900">32</xref>). Acupoint sticking therapy is a noninvasive pain acupoint therapy based on meridian theory of traditional Chinese medicine (TCM), which is used to treat diseases. It is an important component of TCM therapeutics, which are a set of unique and effective treatment methods performed by the working people of China in the struggle with disease. The mechanism of acupoint sticking therapy is complicated. According to the theory of viscera-meridian in TCM, acupoints are closely associated with viscera through meridians, which not only reflect the physiological or pathological functions of each viscera, but also is an effective stimulating point for the treatment of diseases of the viscera (<xref ref-type="bibr" rid="b33-ijmm-43-04-1900">33</xref>).</p>
<p>The PI3K/serine threonine kinase (V-AKT murine thymoma viral oncogene homolog, AKT) pathway is the key signal transduction pathways in eukaryotic cells (<xref ref-type="bibr" rid="b34-ijmm-43-04-1900">34</xref>). It serves an important role in biological activities including apoptosis, metabolism, proliferation and differentiation. The active form of AKT in the body is phosphorylated at 308th site threonine and 473rd site serine. Thr308 phosphorylation serves a role in stabilizing the activation state of AKT, so the detection of the expression of ser473 phosphorylation AKT protein is a marker of the degree of activation of the PI3K/AKT pathway (<xref ref-type="bibr" rid="b35-ijmm-43-04-1900">35</xref>,<xref ref-type="bibr" rid="b36-ijmm-43-04-1900">36</xref>). The PI3K/AKT signaling pathway is closely associated with renal disease. It is demonstrated that regulating the activity of PI3K/AKT can affect the proliferation of mesangial cells and the secretion of the extracellular matrix. In the unilateral ureteral obstruction rat model, the PI3K/AKT signaling pathway was involved in the process of renal interstitial fibrosis (<xref ref-type="bibr" rid="b37-ijmm-43-04-1900">37</xref>,<xref ref-type="bibr" rid="b38-ijmm-43-04-1900">38</xref>). The PI3K/AKT signal transduction pathway is closely associated with cell growth and proliferation. It regulates the development of renal diseases including renal fibrosis, diabetic nephropathy, autosomal dominant polycystic kidney disease and renal cell carcinoma, along with the level of p-AKT in the whole kidney following 4 weeks of diabetes in rats (<xref ref-type="bibr" rid="b39-ijmm-43-04-1900">39</xref>,<xref ref-type="bibr" rid="b40-ijmm-43-04-1900">40</xref>).</p>
<p>In this study, amlodipine besylate combined with AA-TCM nursing in the treatment of renal failure hypertension, can effectively reduce the systolic pressure, diastolic pressure, and improve the symptoms of patients. Amlodipine besylate combined with AA-TCM nursing in the treatment of renal failure hypertension may be associated with the regulation of the expression of the PI3K/AKT pathway gene protein, so as to regulate the expression of BUN, CRE, UP, BUP and NAG.</p>
<p>The present study confirms that amlodipine combined with AA-TCM nursing can effectively treat renal failure hypertension; its antihypertensive effect is very good and the clinical symptoms have been improved. This result is associated with the influence of the PI3K/AKT pathway. The present study provides a clinical basis for the treatment of renal failure and hypertension.</p></sec></body>
<back>
<ack>
<title>Acknowledgments</title>
<p>Not applicable.</p></ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>PI3K</term>
<def>
<p>phosphoinositide 3-kinase</p></def></def-item>
<def-item>
<term>AKT</term>
<def>
<p>protein kinase B</p></def></def-item>
<def-item>
<term>VEGF</term>
<def>
<p>vascular endothelial growth factor</p></def></def-item>
<def-item>
<term>MMP9</term>
<def>
<p>matrix metallopeptidase 9</p></def></def-item>
<def-item>
<term>ET-1</term>
<def>
<p>endothelin-1</p></def></def-item>
<def-item>
<term>NF-&#x003BA;B p65</term>
<def>
<p>nuclear factor-&#x003BA;B p65</p></def></def-item>
<def-item>
<term>BUN</term>
<def>
<p>blood urea nitrogen</p></def></def-item>
<def-item>
<term>CRE</term>
<def>
<p>carbapenem-resistant Enterobacteriaceae</p></def></def-item>
<def-item>
<term>NAG</term>
<def>
<p>N-acetyl-&#x003B2;-D-glucosaminidase</p></def></def-item>
<def-item>
<term>Ccr</term>
<def>
<p>creatinine clearance</p></def></def-item>
<def-item>
<term>TP</term>
<def>
<p>total protein</p></def></def-item>
<def-item>
<term>UP</term>
<def>
<p>urine protein</p></def></def-item></def-list></glossary>
<sec sec-type="other">
<title>Funding</title>
<p>The present study was supported by the Traditional Chinese Medicine Science and Technology Development Program of Shandong Province (grant no. 2017-387).</p></sec>
<sec sec-type="materials">
<title>Availability of data and materials</title>
<p>All data generated or analyzed during this study are included in this published article.</p></sec>
<sec sec-type="other">
<title>Authors&#x02019; contributions</title>
<p>LF, RC and WL conceived and designed the experiments. LF, JS, RC, QZ, SL and WL performed the experiments, prepared the manuscript and analyzed the data. All authors read and approved the final version of the manuscript.</p></sec>
<sec sec-type="other">
<title>Ethics approval and consent to participate</title>
<p>The study was approved by the Yantai Traditional Chinese Medicine Hospital (Yantai, China). Informed consent was obtained from all participants. All included patients fulfilled criteria and completed the study.</p></sec>
<sec sec-type="other">
<title>Patient consent for publication</title>
<p>All participants provided written informed consent.</p></sec>
<sec sec-type="other">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p></sec>
<ref-list>
<title>References</title>
<ref id="b1-ijmm-43-04-1900"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Atkins</surname><given-names>R</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>EP</given-names></name><name><surname>Collins</surname><given-names>AJ</given-names></name><name><surname>Eckardt</surname><given-names>KU</given-names></name><name><surname>Nahas</surname><given-names>ME</given-names></name><name><surname>Jaber</surname><given-names>BL</given-names></name><name><surname>Jadoul</surname><given-names>M</given-names></name><name><surname>Levin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Chronic kidney disease as a global public health problem: Approaches and initiatives-a position statement from kidney disease improving global outcomes</article-title><source>Kidney Int</source><volume>72</volume><fpage>247</fpage><lpage>259</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/sj.ki.5002343</pub-id><pub-id pub-id-type="pmid">17568785</pub-id></element-citation></ref>
<ref id="b2-ijmm-43-04-1900"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoccali</surname><given-names>C</given-names></name><name><surname>Kramer</surname><given-names>A</given-names></name><name><surname>Jager</surname><given-names>KJ</given-names></name></person-group><article-title>Chronic kidney disease and end-stage renal disease-a review produced to contribute to the report &#x02018;the status of health in the European union: Towards a healthier Europe&#x02019;</article-title><source>NDT Plus</source><volume>3</volume><fpage>213</fpage><lpage>224</lpage><year>2010</year><pub-id pub-id-type="pmid">28657040</pub-id><pub-id pub-id-type="pmcid">5477935</pub-id></element-citation></ref>
<ref id="b3-ijmm-43-04-1900"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Br&#x000FC;ck</surname><given-names>K</given-names></name><name><surname>Stel</surname><given-names>VS</given-names></name><name><surname>Gambaro</surname><given-names>G</given-names></name><name><surname>Hallan</surname><given-names>S</given-names></name><name><surname>V&#x000F6;lzke</surname><given-names>H</given-names></name><name><surname>&#x000C4;rnl&#x000F6;v</surname><given-names>J</given-names></name><name><surname>Kastarinen</surname><given-names>M</given-names></name><name><surname>Guessous</surname><given-names>I</given-names></name><name><surname>Vinhas</surname><given-names>J</given-names></name><name><surname>Stengel</surname><given-names>B</given-names></name><etal/></person-group><article-title>CKD prevalence varies across the European general population</article-title><source>J Am Soc Nephrol</source><volume>27</volume><fpage>2135</fpage><lpage>2147</lpage><year>2016</year><pub-id pub-id-type="doi">10.1681/ASN.2015050542</pub-id><pub-id pub-id-type="pmcid">4926978</pub-id></element-citation></ref>
<ref id="b4-ijmm-43-04-1900"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Symplicity HTN-2 Investigators</collab><name><surname>Esler</surname><given-names>MD</given-names></name><name><surname>Krum</surname><given-names>H</given-names></name><name><surname>Sobotka</surname><given-names>PA</given-names></name><name><surname>Schlaich</surname><given-names>MP</given-names></name><name><surname>Schmieder</surname><given-names>RE</given-names></name><name><surname>B&#x000F6;hm</surname><given-names>M</given-names></name></person-group><article-title>Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial</article-title><source>Lancet</source><volume>376</volume><fpage>1903</fpage><lpage>1909</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/S0140-6736(10)62039-9</pub-id><pub-id pub-id-type="pmid">21093036</pub-id></element-citation></ref>
<ref id="b5-ijmm-43-04-1900"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makani</surname><given-names>H</given-names></name><name><surname>Bangalore</surname><given-names>S</given-names></name><name><surname>Romero</surname><given-names>J</given-names></name><name><surname>Wever-Pinzon</surname><given-names>O</given-names></name><name><surname>Messerli</surname><given-names>FH</given-names></name></person-group><article-title>Effect of renin-angiotensin system blockade on calcium channel blocker associated peripheral edema</article-title><source>Am J Med</source><volume>124</volume><fpage>128</fpage><lpage>135</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.amjmed.2010.08.007</pub-id><pub-id pub-id-type="pmid">21295192</pub-id></element-citation></ref>
<ref id="b6-ijmm-43-04-1900"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitrow</surname><given-names>PP</given-names></name><name><surname>Jawien</surname><given-names>M</given-names></name></person-group><article-title>Anti-inflammatory effect of atorvastatin in patients with aortic sclerosis or mild aortic stenosis independent of hypercholesterolemia</article-title><source>Pharmacol Rep</source><volume>62</volume><fpage>1250</fpage><lpage>1254</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/S1734-1140(10)70390-X</pub-id></element-citation></ref>
<ref id="b7-ijmm-43-04-1900"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benicky</surname><given-names>J</given-names></name><name><surname>Sanchez-Lemus</surname><given-names>E</given-names></name><name><surname>Honda</surname><given-names>M</given-names></name><name><surname>Pang</surname><given-names>T</given-names></name><name><surname>Orecna</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Leng</surname><given-names>Y</given-names></name><name><surname>Chuang</surname><given-names>DM</given-names></name><name><surname>Saavedra</surname><given-names>JM</given-names></name></person-group><article-title>Angiotensin II AT1 receptor blockade ameliorates brain inflammation</article-title><source>Neuropsychopharmacology</source><volume>36</volume><fpage>857</fpage><lpage>870</lpage><year>2011</year><pub-id pub-id-type="doi">10.1038/npp.2010.225</pub-id><pub-id pub-id-type="pmcid">3055735</pub-id></element-citation></ref>
<ref id="b8-ijmm-43-04-1900"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name></person-group><article-title>Chronic unilateral chemosis following the use of amlodipine besylate</article-title><source>BMC Ophthalmol</source><volume>14</volume><fpage>124</fpage><year>2014</year><pub-id pub-id-type="doi">10.1186/1471-2415-14-124</pub-id><pub-id pub-id-type="pmid">25335530</pub-id><pub-id pub-id-type="pmcid">4216336</pub-id></element-citation></ref>
<ref id="b9-ijmm-43-04-1900"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Tuohayi</surname><given-names>J</given-names></name></person-group><article-title>Ginsenoside Rg3 promotes the antitumor activity of gefitinib in lung cancer cell lines</article-title><source>Exp Ther Med</source><volume>17</volume><fpage>953</fpage><lpage>959</lpage><year>2019</year><pub-id pub-id-type="pmid">30651886</pub-id><pub-id pub-id-type="pmcid">6307378</pub-id></element-citation></ref>
<ref id="b10-ijmm-43-04-1900"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>XA</given-names></name><name><surname>Dai</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>ZZ</given-names></name><name><surname>Song</surname><given-names>QH</given-names></name></person-group><article-title>Treatment of facial acne vulgaris by chinese medicine combined western medicine</article-title><source>Zhongguo Zhong Xi Yi Jie He Za Zhi</source><volume>37</volume><fpage>160</fpage><lpage>164</lpage><year>2017</year><comment>In Chinese</comment><pub-id pub-id-type="pmid">30650266</pub-id></element-citation></ref>
<ref id="b11-ijmm-43-04-1900"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>B</given-names></name><name><surname>Man</surname><given-names>L</given-names></name></person-group><article-title>Acupoint application for asthma therapy in adults: A systematic review and meta-analysis of randomized controlled trials</article-title><source>Forsch Komplementmed</source><volume>23</volume><fpage>16</fpage><lpage>21</lpage><year>2016</year><pub-id pub-id-type="pmid">26978427</pub-id></element-citation></ref>
<ref id="b12-ijmm-43-04-1900"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>CY</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>LY</given-names></name><name><surname>He</surname><given-names>YM</given-names></name><name><surname>Wang</surname><given-names>HS</given-names></name><name><surname>Wu</surname><given-names>WZ</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title>Inhibitory effect of acupoint application on airway remodeling and expression of TGF-&#x003B2; 1/Smad 3 in the lung tissue of chronic asthma mice</article-title><source>Zhen Ci Yan Jiu</source><volume>42</volume><fpage>153</fpage><lpage>158</lpage><year>2017</year><comment>In Chinese</comment><pub-id pub-id-type="pmid">29071965</pub-id></element-citation></ref>
<ref id="b13-ijmm-43-04-1900"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fresno Vara</surname><given-names>JA</given-names></name><name><surname>Casado</surname><given-names>E</given-names></name><name><surname>de Castro</surname><given-names>J</given-names></name><name><surname>Cejas</surname><given-names>P</given-names></name><name><surname>Belda-Iniesta</surname><given-names>C</given-names></name><name><surname>Gonz&#x000E1;lez-Bar&#x000F3;n</surname><given-names>M</given-names></name></person-group><article-title>PI3K/AKT signalling pathway and cancer</article-title><source>Cancer Treat Rev</source><volume>30</volume><fpage>193</fpage><lpage>204</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.ctrv.2003.07.007</pub-id><pub-id pub-id-type="pmid">15023437</pub-id></element-citation></ref>
<ref id="b14-ijmm-43-04-1900"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Que</surname><given-names>L</given-names></name><name><surname>Ha</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/AKT-dependent mechanism</article-title><source>Surgery</source><volume>146</volume><fpage>506</fpage><lpage>514</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.surg.2009.03.022</pub-id><pub-id pub-id-type="pmid">19715808</pub-id></element-citation></ref>
<ref id="b15-ijmm-43-04-1900"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tramontano</surname><given-names>AF</given-names></name><name><surname>Muniyappa</surname><given-names>R</given-names></name><name><surname>Black</surname><given-names>AD</given-names></name><name><surname>Blendea</surname><given-names>MC</given-names></name><name><surname>Cohen</surname><given-names>I</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name><name><surname>Cutaia</surname><given-names>MV</given-names></name><name><surname>El-Sherif</surname><given-names>N</given-names></name></person-group><article-title>Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an AKT-dependent pathway</article-title><source>Biochem Biophys Res Commun</source><volume>308</volume><fpage>990</fpage><lpage>994</lpage><year>2003</year><pub-id pub-id-type="doi">10.1016/S0006-291X(03)01503-1</pub-id><pub-id pub-id-type="pmid">12927817</pub-id></element-citation></ref>
<ref id="b16-ijmm-43-04-1900"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Lan</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Pei</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Administration of dexamethasone protects mice against ischemia/reperfusion induced renal injury by suppressing PI3K/AKT signaling</article-title><source>Int J Clin Exp Pathol</source><volume>6</volume><fpage>2366</fpage><lpage>2375</lpage><year>2013</year><pub-id pub-id-type="pmid">24228098</pub-id><pub-id pub-id-type="pmcid">3816805</pub-id></element-citation></ref>
<ref id="b17-ijmm-43-04-1900"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name></person-group><article-title>Role of PI3-kinase/AKT signalling pathway in renal function and cell proliferation after renal ischaemia/reperfusion injury in mice</article-title><source>Nephrology (Carlton)</source><volume>11</volume><fpage>207</fpage><lpage>212</lpage><year>2006</year><pub-id pub-id-type="doi">10.1111/j.1440-1797.2006.00558.x</pub-id></element-citation></ref>
<ref id="b18-ijmm-43-04-1900"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matheny</surname><given-names>RW</given-names></name><name><surname>Adam</surname><given-names>ML</given-names></name></person-group><article-title>Current perspectives on AKTAKT-ivation and AKT-ions</article-title><source>Exp Biol Med (Maywood)</source><volume>234</volume><fpage>1264</fpage><lpage>1270</lpage><year>2009</year><pub-id pub-id-type="doi">10.3181/0904-MR-138</pub-id></element-citation></ref>
<ref id="b19-ijmm-43-04-1900"><label>19</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><etal/></person-group><source>The guideline 2010 for hypertension prevention and treatment in China</source><edition>3rd edition</edition><year>2010</year><comment><ext-link xlink:href="http://csjfyy.com/articles/E/020/010/050.pdf" ext-link-type="uri">http://csjfyy.com/articles/E/020/010/050.pdf</ext-link></comment></element-citation></ref>
<ref id="b20-ijmm-43-04-1900"><label>20</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Research Council</collab></person-group><source>The Guide for the Care and Use of Laboratory Animals</source><publisher-name>National Academies Press</publisher-name><publisher-name>Washington DC</publisher-name><comment>revised</comment><year>1996</year></element-citation></ref>
<ref id="b21-ijmm-43-04-1900"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id></element-citation></ref>
<ref id="b22-ijmm-43-04-1900"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Kandzari</surname><given-names>DE</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>WW</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>R</given-names></name><name><surname>Flack</surname><given-names>JM</given-names></name><name><surname>Katzen</surname><given-names>BT</given-names></name><name><surname>Leon</surname><given-names>MB</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Mauri</surname><given-names>L</given-names></name><name><surname>Negoita</surname><given-names>M</given-names></name><etal/></person-group><article-title>A controlled trial of renal denervation for resistant hypertension</article-title><source>N Engl J Med</source><volume>370</volume><fpage>1393</fpage><lpage>1401</lpage><year>2014</year><pub-id pub-id-type="doi">10.1056/NEJMoa1402670</pub-id><pub-id pub-id-type="pmid">24678939</pub-id></element-citation></ref>
<ref id="b23-ijmm-43-04-1900"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoccali</surname><given-names>C</given-names></name><name><surname>Tripepi</surname><given-names>R</given-names></name><name><surname>Torino</surname><given-names>C</given-names></name><name><surname>Tripepi</surname><given-names>G</given-names></name><name><surname>Mallamaci</surname><given-names>F</given-names></name></person-group><article-title>Moderator&#x02019;s view: Ambulatory blood pressure monitoring and home blood pressure for the prognosis, diagnosis and treatment of hypertension in dialysis patients</article-title><source>Nephrol Dial Transplant</source><volume>30</volume><fpage>1443</fpage><lpage>1448</lpage><year>2015</year><pub-id pub-id-type="doi">10.1093/ndt/gfv241</pub-id><pub-id pub-id-type="pmid">26022727</pub-id></element-citation></ref>
<ref id="b24-ijmm-43-04-1900"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azizi</surname><given-names>M</given-names></name><name><surname>Sapoval</surname><given-names>M</given-names></name><name><surname>Gosse</surname><given-names>P</given-names></name><name><surname>Monge</surname><given-names>M</given-names></name><name><surname>Bobrie</surname><given-names>G</given-names></name><name><surname>Delsart</surname><given-names>P</given-names></name><name><surname>Midulla</surname><given-names>M</given-names></name><name><surname>Mounier-V&#x000E9;hier</surname><given-names>C</given-names></name><name><surname>Courand</surname><given-names>PY</given-names></name><name><surname>Lantelme</surname><given-names>P</given-names></name><etal/></person-group><article-title>Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): A multicentre, open-label, randomised controlled trial</article-title><source>Lancet</source><volume>385</volume><fpage>1957</fpage><lpage>1965</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/S0140-6736(14)61942-5</pub-id><pub-id pub-id-type="pmid">25631070</pub-id></element-citation></ref>
<ref id="b25-ijmm-43-04-1900"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>R</given-names></name></person-group><article-title>Pro: Ambulatory blood pressure should be used in all patients on hemodialysis</article-title><source>Nephrol Dial Transplant</source><volume>30</volume><fpage>1432</fpage><lpage>1437</lpage><year>2015</year><pub-id pub-id-type="doi">10.1093/ndt/gfv243</pub-id><pub-id pub-id-type="pmid">26022728</pub-id><pub-id pub-id-type="pmcid">4675929</pub-id></element-citation></ref>
<ref id="b26-ijmm-43-04-1900"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jardine</surname><given-names>AG</given-names></name></person-group><article-title>Con: Ambulatory blood pressure measurement in patients receiving haemodialysis: A sore arm and a waste of time?</article-title><source>Nephrol Dial Transplant</source><volume>30</volume><fpage>1438</fpage><lpage>1441</lpage><year>2015</year><pub-id pub-id-type="doi">10.1093/ndt/gfv244</pub-id><pub-id pub-id-type="pmid">26022726</pub-id></element-citation></ref>
<ref id="b27-ijmm-43-04-1900"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bansal</surname><given-names>N</given-names></name><name><surname>McCulloch</surname><given-names>CE</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name><name><surname>Kusek</surname><given-names>JW</given-names></name><name><surname>Anderson</surname><given-names>AH</given-names></name><name><surname>Xie</surname><given-names>D</given-names></name><name><surname>Townsend</surname><given-names>RR</given-names></name><name><surname>Lora</surname><given-names>CM</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: The chronic renal insufficiency cohort study</article-title><source>Hypertension</source><volume>65</volume><fpage>93</fpage><lpage>100</lpage><year>2015</year><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.114.04334</pub-id></element-citation></ref>
<ref id="b28-ijmm-43-04-1900"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Say</surname><given-names>EA</given-names></name><name><surname>Shields</surname><given-names>CL</given-names></name><name><surname>Bianciotto</surname><given-names>C</given-names></name><name><surname>Shields</surname><given-names>JA</given-names></name></person-group><article-title>Chronic conjunctival chemosis from amlodipine besylate (Norvasc)</article-title><source>Cornea</source><volume>30</volume><fpage>604</fpage><lpage>607</lpage><year>2011</year><pub-id pub-id-type="doi">10.1097/ICO.0b013e3181fb8169</pub-id></element-citation></ref>
<ref id="b29-ijmm-43-04-1900"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedrinelli</surname><given-names>R</given-names></name><name><surname>Dell&#x02019;Omo</surname><given-names>G</given-names></name><name><surname>Mariani</surname><given-names>M</given-names></name></person-group><article-title>Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension</article-title><source>J Hum Hypertens</source><volume>15</volume><fpage>455</fpage><lpage>461</lpage><year>2001</year><pub-id pub-id-type="doi">10.1038/sj.jhh.1001201</pub-id><pub-id pub-id-type="pmid">11464254</pub-id></element-citation></ref>
<ref id="b30-ijmm-43-04-1900"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moes</surname><given-names>AD</given-names></name><name><surname>Hesselink</surname><given-names>DA</given-names></name><name><surname>van den Meiracker</surname><given-names>AH</given-names></name><name><surname>Zietse</surname><given-names>R</given-names></name><name><surname>Hoorn</surname><given-names>EJ</given-names></name></person-group><article-title>Chlorthalidone versus amlodipine for hypertension in kidney transplant recipients treated with tacrolimus: A randomized crossover trial</article-title><source>Am J Kidney Dis</source><volume>69</volume><fpage>796</fpage><lpage>804</lpage><year>2017</year><pub-id pub-id-type="doi">10.1053/j.ajkd.2016.12.017</pub-id><pub-id pub-id-type="pmid">28259499</pub-id></element-citation></ref>
<ref id="b31-ijmm-43-04-1900"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houben</surname><given-names>AJ</given-names></name><name><surname>Burgwinkel</surname><given-names>JP</given-names></name><name><surname>de Leeuw</surname><given-names>PW</given-names></name></person-group><article-title>A novel approach to the study of human microcirculation: Reactivity to locally applied angiotensin II in the conjunctivalmicrovascular bed</article-title><source>J Hypertens</source><volume>24</volume><fpage>2225</fpage><lpage>2230</lpage><year>2006</year><pub-id pub-id-type="doi">10.1097/01.hjh.0000249700.11736.9e</pub-id><pub-id pub-id-type="pmid">17053544</pub-id></element-citation></ref>
<ref id="b32-ijmm-43-04-1900"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weir</surname><given-names>MR</given-names></name><name><surname>Rosenberger</surname><given-names>C</given-names></name><name><surname>Fink</surname><given-names>JC</given-names></name></person-group><article-title>Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihy-dropyridine calcium antagonists</article-title><source>Am J Hypertens</source><volume>14</volume><fpage>963</fpage><lpage>968</lpage><year>2001</year><pub-id pub-id-type="doi">10.1016/S0895-7061(01)02167-7</pub-id><pub-id pub-id-type="pmid">11587165</pub-id></element-citation></ref>
<ref id="b33-ijmm-43-04-1900"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Gu</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>F</given-names></name><name><surname>Zhuang</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>Moderate and severe persistent allergic rhinitis treated with acupoint application therapy of the different intensity: A randomized controlled trial</article-title><source>Zhongguo Zhen Jiu</source><volume>37</volume><fpage>1177</fpage><lpage>1182</lpage><year>2017</year><comment>In Chinese</comment></element-citation></ref>
<ref id="b34-ijmm-43-04-1900"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ooms</surname><given-names>LM</given-names></name><name><surname>Fedele</surname><given-names>CG</given-names></name><name><surname>Astle</surname><given-names>MV</given-names></name><name><surname>Ivetac</surname><given-names>I</given-names></name><name><surname>Cheung</surname><given-names>V</given-names></name><name><surname>Pearson</surname><given-names>RB</given-names></name><name><surname>Layton</surname><given-names>MJ</given-names></name><name><surname>Forrai</surname><given-names>A</given-names></name><name><surname>Nandurkar</surname><given-names>HH</given-names></name><name><surname>Mitchell</surname><given-names>CA</given-names></name></person-group><article-title>The inositol polyphosphate 5-phosphatase, PIPP, is a novel regulator of phosphoinositide 3-kinase-dependent neurite elongation</article-title><source>Mol Biol Cell</source><volume>17</volume><fpage>607</fpage><lpage>622</lpage><year>2006</year><pub-id pub-id-type="doi">10.1091/mbc.e05-05-0469</pub-id><pub-id pub-id-type="pmcid">1356573</pub-id></element-citation></ref>
<ref id="b35-ijmm-43-04-1900"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jean</surname><given-names>S</given-names></name><name><surname>Kiger</surname><given-names>AA</given-names></name></person-group><article-title>Classes of phosphoinositide 3-kinases at a glance</article-title><source>J Cell Sci</source><volume>127</volume><fpage>923</fpage><lpage>928</lpage><year>2014</year><pub-id pub-id-type="doi">10.1242/jcs.093773</pub-id><pub-id pub-id-type="pmid">24587488</pub-id><pub-id pub-id-type="pmcid">3937771</pub-id></element-citation></ref>
<ref id="b36-ijmm-43-04-1900"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheid</surname><given-names>MP</given-names></name><name><surname>Huber</surname><given-names>M</given-names></name><name><surname>Damen</surname><given-names>JE</given-names></name><name><surname>Hughes</surname><given-names>M</given-names></name><name><surname>Kang</surname><given-names>V</given-names></name><name><surname>Neilsen</surname><given-names>P</given-names></name><name><surname>Prestwich</surname><given-names>GD</given-names></name><name><surname>Krystal</surname><given-names>G</given-names></name><name><surname>Duronio</surname><given-names>V</given-names></name></person-group><article-title>Phosphatidylinositol (3,4,5) P3 is essential but not sufficient for protein kinase B (PKB) activation phosphatidylinositol (3,4) P2 is required for PKB phosphorylation at Ser-473: Studies using cells from SH2-containing inositol5-phosphatase knockout mice</article-title><source>J Biol Chem</source><volume>277</volume><fpage>9027</fpage><lpage>9035</lpage><year>2002</year><pub-id pub-id-type="doi">10.1074/jbc.M106755200</pub-id><pub-id pub-id-type="pmid">11781306</pub-id></element-citation></ref>
<ref id="b37-ijmm-43-04-1900"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Cheung</surname><given-names>SM</given-names></name><name><surname>Marshall</surname><given-names>AJ</given-names></name><name><surname>Duronio</surname><given-names>V</given-names></name></person-group><article-title>PI(3,4,5)P3 and PI(3,4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively PI(3,4)P2 levels determine PKB activity</article-title><source>Cell Signal</source><volume>20</volume><fpage>684</fpage><lpage>694</lpage><year>2008</year><pub-id pub-id-type="doi">10.1016/j.cellsig.2007.12.004</pub-id><pub-id pub-id-type="pmid">18249092</pub-id></element-citation></ref>
<ref id="b38-ijmm-43-04-1900"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Marshall</surname><given-names>AJ</given-names></name></person-group><article-title>Phosphatidylinositol (3,4) bisphosphate-specific phosphatases and effector proteins: A distinct branch of PI3K signaling</article-title><source>Cell Signal</source><volume>27</volume><fpage>1789</fpage><lpage>1798</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.cellsig.2015.05.013</pub-id><pub-id pub-id-type="pmid">26022180</pub-id></element-citation></ref>
<ref id="b39-ijmm-43-04-1900"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoki</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><article-title>TSC2 is phosphorylated and inhibited by AKT and suppresses mTOR signalling</article-title><source>Nat Cell Biol</source><volume>4</volume><fpage>648</fpage><lpage>657</lpage><year>2002</year><pub-id pub-id-type="doi">10.1038/ncb839</pub-id><pub-id pub-id-type="pmid">12172553</pub-id></element-citation></ref>
<ref id="b40-ijmm-43-04-1900"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Ijuin</surname><given-names>T</given-names></name><name><surname>Itoh</surname><given-names>T</given-names></name><name><surname>Takenawa</surname><given-names>T</given-names></name></person-group><article-title>Regulation of IGF-1/PI3K/AKT signaling by the phosphoinositide phosphatase pharbin</article-title><source>J Biochem</source><volume>150</volume><fpage>83</fpage><lpage>93</lpage><year>2011</year><pub-id pub-id-type="doi">10.1093/jb/mvr037</pub-id><pub-id pub-id-type="pmid">21436142</pub-id></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-ijmm-43-04-1900" position="float">
<label>Figure 1</label>
<caption>
<p>Effect of amlodipine besylate combined with acupoint application on blood pressure in hypertension rats with renal failure. (A) Changes in systolic blood pressure in rats. (B) changes in DBP in rats. <sup>&#x0002A;</sup>P&#x0003C;0.05 vs. the Sham group, <sup>#</sup>P&#x0003C;0.05 vs. the Model group. <sup>&#x00026;</sup>P&#x0003C;0.05 vs. the NC group. NC, negative control; DBP, diastolic blood pressure; SBP, systolic blood pressure.</p></caption>
<graphic xlink:href="IJMM-43-04-1900-g00.tif"/></fig>
<fig id="f2-ijmm-43-04-1900" position="float">
<label>Figure 2</label>
<caption>
<p>Effect of amlodipine besylate combined with acupoint application on blood biochemical indexes in hypertension rats with renal failure. (A) The concentrations of BUN. (B) The concentration of CRE. (C) The concentration of TP. (D) The concentration of ALB. <sup>&#x0002A;</sup>P&#x0003C;0.05 vs. the Sham group and <sup>#</sup>P&#x0003C;0.05 vs. the Model group. NC, negative control; CRE, carbapenem-resistant Enterobacteriaceae; TP, total protein; BUN, blood urea nitrogen; ALB, albumin.</p></caption>
<graphic xlink:href="IJMM-43-04-1900-g01.tif"/></fig>
<fig id="f3-ijmm-43-04-1900" position="float">
<label>Figure 3</label>
<caption>
<p>Effect of amlodipine besylate combined with acupoint application on urine index in hypertension rats with renal failure. (A) The content of UP. (B) The content of BUP. (C) The content of CRE. (D) The content of NAG. (E) Ccr. <sup>&#x0002A;</sup>P&#x0003C;0.05 vs. the Sham group, <sup>#</sup>P&#x0003C;0.05 vs. the Model group and <sup>&#x00026;</sup>P&#x0003C;0.05 vs. the NC group. NC, negative control; UP, urine protein; BUP, blood urea protein; NAG, N-acetyl-&#x003B2;-D-glucosaminidase; CRE, carbapenem-resistant Enterobacteriaceae; Ccr Creatinine clearance rate.</p></caption>
<graphic xlink:href="IJMM-43-04-1900-g02.tif"/></fig>
<fig id="f4-ijmm-43-04-1900" position="float">
<label>Figure 4</label>
<caption>
<p>Pathological alterations of renal tissue in rats with hematoxylin and eosin staining (magnification, &#x000D7;200). NC, negative control.</p></caption>
<graphic xlink:href="IJMM-43-04-1900-g03.tif"/></fig>
<fig id="f5-ijmm-43-04-1900" position="float">
<label>Figure 5</label>
<caption>
<p>Effect of amlodipine besylate combined acupoint application on VEGF and MMP9 in renal tissue of hypertensive rats with renal failure. (A) Immunohistochemistry. (B) VEGF immunohistochemical score. (C) MMP9 immunohistochemical score. <sup>&#x0002A;</sup>P&#x0003C;0.05 vs. the Sham group, <sup>#</sup>P&#x0003C;0.05 vs. the Model group and <sup>&#x00026;</sup>P&#x0003C;0.05 vs. the NC group. VEGF, vascular endothelial growth factor; MMP, matrix metalloproteinase; NC, negative control.</p></caption>
<graphic xlink:href="IJMM-43-04-1900-g04.tif"/></fig>
<fig id="f6-ijmm-43-04-1900" position="float">
<label>Figure 6</label>
<caption>
<p>Effect of amlodipine besylate combined acupoint application on PI3K/AKT pathway related mRNA in hypertensive rats with renal failure. (A) The mRNA expression of PI3K. (B) The mRNA expression of AKT. (C) The mRNA expression of ET-1 mRNA. <sup>&#x0002A;</sup>P&#x0003C;0.05 vs. the Sham group, <sup>#</sup>P&#x0003C;0.05 vs. the Model group, <sup>&#x00026;</sup>P&#x0003C;0.05 vs. the NC group. AKT, protein kinase B; PI3K, phosphoinositide 3-kinase; NC, negative control.</p></caption>
<graphic xlink:href="IJMM-43-04-1900-g05.tif"/></fig>
<fig id="f7-ijmm-43-04-1900" position="float">
<label>Figure 7</label>
<caption>
<p>Effect of amlodipine besylate combined acupoint application on PI3K/AKT pathway related proteins in hypertensive rats with renal failure. (A) Western blotting. (B) The expression of p-PI3K/PI3K protein. (C) The expression of p-AKT/AKT protein. (D) The expression of p-NF-&#x003BA;B p65/NF-&#x003BA;B p65 protein. <sup>&#x0002A;</sup>P&#x0003C;0.05 vs. the Sham group, <sup>#</sup>P&#x0003C;0.05 vs. the Model group and <sup>&#x00026;</sup>P&#x0003C;0.05 vs. the NC group. P, phosphorylated; AKT, protein kinase B; p-PI3K, phosphorylated phosphoinositide 3-kinase; NF, nuclear factor.</p></caption>
<graphic xlink:href="IJMM-43-04-1900-g06.tif"/></fig>
<table-wrap id="tI-ijmm-43-04-1900" position="float">
<label>Table I</label>
<caption>
<p>The primer sequences used in the present study.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Gene</th>
<th valign="top" align="left">Sequence</th></tr></thead>
<tbody>
<tr>
<td rowspan="2" valign="top" align="left">PI3K</td>
<td valign="top" align="left">Forward: 5&#x02032;-CAATACTTGATGTGGCTGAC-3&#x02032;</td></tr>
<tr>
<td valign="top" align="left">Reverse: 5&#x02032;-CAATACTTGATGTGGCTGAC-3&#x02032;</td></tr>
<tr>
<td rowspan="2" valign="top" align="left">AKT</td>
<td valign="top" align="left">Forward: 5&#x02032;-TTTATTGGCTACAAGGAACG-3&#x02032;</td></tr>
<tr>
<td valign="top" align="left">Reverse: 5&#x02032;-AGTCTGAATGGCGGTGGT-3&#x02032;</td></tr>
<tr>
<td rowspan="2" valign="top" align="left">ET-1</td>
<td valign="top" align="left">Forward: 5&#x02032;-TCTCTGCTGTTTGTGGCTTTC-3&#x02032;</td></tr>
<tr>
<td valign="top" align="left">Reverse: 5&#x02032;-TCGGAGTTCTTTGTCTGCTTG-3&#x02032;</td></tr>
<tr>
<td rowspan="2" valign="top" align="left">&#x003B2;-actin</td>
<td valign="top" align="left">Forward: 5&#x02032;-TCAGGTCATCACTATCGGCAAT-3&#x02032;</td></tr>
<tr>
<td valign="top" align="left">Reverse: 5&#x02032;- AAAGAAAGGGAGTAAAACGCA-3&#x02032;</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-ijmm-43-04-1900">
<p>AKT, protein kinase B; ET, endothelin; PI3K, phosphoinositide 3-kinase.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tII-ijmm-43-04-1900" position="float">
<label>Table II</label>
<caption>
<p>Changes in blood pressure before and after treatment in two groups.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th rowspan="2" valign="top" align="left">Index</th>
<th colspan="2" valign="top" align="center">Control group
<hr/></th>
<th colspan="2" valign="top" align="center">Treatment group
<hr/></th></tr>
<tr>
<th valign="top" align="center">Before treatment</th>
<th valign="top" align="center">After treatment</th>
<th valign="top" align="center">Before treatment</th>
<th valign="top" align="center">After treatment</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">SBP</td>
<td valign="top" align="center">159.10&#x000B1;11.29</td>
<td valign="top" align="center">139.83&#x000B1;11.93<xref rid="tfn2-ijmm-43-04-1900" ref-type="table-fn">a</xref></td>
<td valign="top" align="center">162.07&#x000B1;14.74</td>
<td valign="top" align="center">133.43&#x000B1;10.52<xref rid="tfn2-ijmm-43-04-1900" ref-type="table-fn">a</xref>,<xref rid="tfn3-ijmm-43-04-1900" ref-type="table-fn">b</xref></td></tr>
<tr>
<td valign="top" align="left">DBP</td>
<td valign="top" align="center">93.60&#x000B1;11.97</td>
<td valign="top" align="center">84.37&#x000B1;10.01<xref rid="tfn2-ijmm-43-04-1900" ref-type="table-fn">a</xref></td>
<td valign="top" align="center">90.67&#x000B1;9.81</td>
<td valign="top" align="center">79.53&#x000B1;8.52<xref rid="tfn2-ijmm-43-04-1900" ref-type="table-fn">a</xref>,<xref rid="tfn3-ijmm-43-04-1900" ref-type="table-fn">b</xref></td></tr></tbody></table>
<table-wrap-foot><fn id="tfn2-ijmm-43-04-1900">
<label>a</label>
<p>P&#x0003C;0.05 vs. before treatment,</p></fn><fn id="tfn3-ijmm-43-04-1900">
<label>b</label>
<p>P&#x0003C;0.05 vs. after treatment in the Control group. SBP, systolic bloodpressure; DBP, diastolic blood pressure.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tIII-ijmm-43-04-1900" position="float">
<label>Table III</label>
<caption>
<p>Effect of the treatment group on hypertensive patients with renal failure.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left"/>
<th valign="top" align="center">Obvious effective (%)</th>
<th valign="top" align="center">Effective (%)</th>
<th valign="top" align="center">No effective (%)</th>
<th valign="top" align="center">Total effective rate (%)</th>
<th valign="top" align="center">P-value</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Control group</td>
<td valign="top" align="right"/>
<td valign="top" align="left"/>
<td valign="top" align="left"/>
<td valign="top" align="right"/>
<td valign="top" align="left">0.09</td></tr>
<tr>
<td valign="top" align="left">Age</td>
<td valign="top" align="right"/>
<td valign="top" align="left"/>
<td valign="top" align="left"/>
<td valign="top" align="right"/>
<td valign="top" align="left"/></tr>
<tr>
<td valign="top" align="left">&#x02003;25-45</td>
<td valign="top" align="right">1 (20.0)</td>
<td valign="top" align="left">0 (0.0)</td>
<td valign="top" align="left">4 (80.0)</td>
<td valign="top" align="right">1 (20.0)</td>
<td valign="top" align="left"/></tr>
<tr>
<td valign="top" align="left">&#x02003;46-65</td>
<td valign="top" align="right">6 (42.9)</td>
<td valign="top" align="left">2 (14.3)</td>
<td valign="top" align="left">6 (42.9)</td>
<td valign="top" align="right">8 (57.1)</td>
<td valign="top" align="left"/></tr>
<tr>
<td valign="top" align="left">&#x02003;66-85</td>
<td valign="top" align="right">3 (30.0)</td>
<td valign="top" align="left">4 (40.0)</td>
<td valign="top" align="left">4 (40.0)</td>
<td valign="top" align="right">7 (70.0)</td>
<td valign="top" align="left"/></tr>
<tr>
<td valign="top" align="left">Sex</td>
<td valign="top" align="right"/>
<td valign="top" align="left"/>
<td valign="top" align="left"/>
<td valign="top" align="right"/>
<td valign="top" align="left">1.000</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Male</td>
<td valign="top" align="right">4 (26.7)</td>
<td valign="top" align="left">4 (26.7)</td>
<td valign="top" align="left">7 (46.7)</td>
<td valign="top" align="right">8 (72.7)</td>
<td valign="top" align="left"/></tr>
<tr>
<td valign="top" align="left">&#x02003;Female</td>
<td valign="top" align="right">6 (40.0)</td>
<td valign="top" align="left">2 (13.3)</td>
<td valign="top" align="left">7 (46.7)</td>
<td valign="top" align="right">8 (53.3)</td>
<td valign="top" align="left"/></tr>
<tr>
<td valign="top" align="left">Treatment group</td>
<td valign="top" align="right"/>
<td valign="top" align="left"/>
<td valign="top" align="left"/>
<td valign="top" align="right"/>
<td valign="top" align="left">0.216</td></tr>
<tr>
<td valign="top" align="left">Age</td>
<td valign="top" align="right"/>
<td valign="top" align="left"/>
<td valign="top" align="left"/>
<td valign="top" align="right"/>
<td valign="top" align="left"/></tr>
<tr>
<td valign="top" align="left">&#x02003;25-45</td>
<td valign="top" align="right">2 (50.0)</td>
<td valign="top" align="left">0 (0.0)</td>
<td valign="top" align="left">2 (50.0)</td>
<td valign="top" align="right">2 (50.0)</td>
<td valign="top" align="left"/></tr>
<tr>
<td valign="top" align="left">&#x02003;46-65</td>
<td valign="top" align="right">11 (73.3)</td>
<td valign="top" align="left">1 (6.7)</td>
<td valign="top" align="left">3 (20.0)</td>
<td valign="top" align="right">12 (80.0)</td>
<td valign="top" align="left"/></tr>
<tr>
<td valign="top" align="left">&#x02003;66-85</td>
<td valign="top" align="right">7 (63.6)</td>
<td valign="top" align="left">3 (27.3)</td>
<td valign="top" align="left">1 (9.1)</td>
<td valign="top" align="right">10 (90.9)</td>
<td valign="top" align="left"/></tr>
<tr>
<td valign="top" align="left">Sex</td>
<td valign="top" align="right"/>
<td valign="top" align="left"/>
<td valign="top" align="left"/>
<td valign="top" align="right"/>
<td valign="top" align="left">0.449</td></tr>
<tr>
<td valign="top" align="left">&#x02003;Male</td>
<td valign="top" align="right">7 (63.6)</td>
<td valign="top" align="left">1 (9.1)</td>
<td valign="top" align="left">3 (27.3)</td>
<td valign="top" align="right">8 (72.7)</td>
<td valign="top" align="left"/></tr>
<tr>
<td valign="top" align="left">&#x02003;Female</td>
<td valign="top" align="right">13 (68.4)</td>
<td valign="top" align="left">3 (15.8)</td>
<td valign="top" align="left">3 (15.8)</td>
<td valign="top" align="right">16 (84.2)</td>
<td valign="top" align="left"/></tr></tbody></table></table-wrap>
<table-wrap id="tIV-ijmm-43-04-1900" position="float">
<label>Table IV</label>
<caption>
<p>The efficacy of treatment in two groups.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Group</th>
<th valign="top" align="center">Obvious effective (%)</th>
<th valign="top" align="center">Effective (%)</th>
<th valign="top" align="center">No effective (%)</th>
<th valign="top" align="center">Total effective rate (%)</th>
<th valign="top" align="center">P-value</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Control group</td>
<td valign="top" align="center">9 (30.0)</td>
<td valign="top" align="center">7 (23.3)</td>
<td valign="top" align="center">14 (46.7)</td>
<td valign="top" align="center">16 (53.3)</td>
<td valign="top" align="center">0.028</td></tr>
<tr>
<td valign="top" align="left">Treat group</td>
<td valign="top" align="center">20 (66.7)</td>
<td valign="top" align="center">4 (13.3)</td>
<td valign="top" align="center">6 (0.2)</td>
<td valign="top" align="center">24 (80.0)</td>
<td valign="top" align="center"/></tr></tbody></table></table-wrap></floats-group></article>
